



Resinco Capital Partners Announces the Appointment of Sir Marc Feldmann to Advisory Board

Vancouver, BC, February 6, 2019 – Resinco Capital Partners Inc. (CSE:RIN, OTC: RSCZF, FRANKFURT: L6V1) (the “**Company**” or “**Resinco**”) is pleased to announce that the Company has appointed pioneer and trailblazer of modern immunology, Sir Marc Feldmann, to its Advisory Board after fully acquiring his company, ReFormation Pharmaceuticals Corp, a medical cannabis company developing innovative, first-in-class therapies to repair vital organs and stem cells by combining cannabinoids and an endogenous trigger of repair.

Sir Marc Feldmann, whose research breakthrough on inflammation led to the creation of some of the world’s top-selling drugs like Humira and Remicade, is embracing medical marijuana through co-founding ReFormation Pharmaceuticals with Professor Jagdeep Nanchahal. Specifically, ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body’s own stem cells to accelerate repair and regeneration following acute or chronic injury.

“As medical marijuana regulations ease, Feldmann is paving the way for a new class of cannabis derived drugs to treat pain and other conditions. His background and expertise will be valuable as we accelerate growth in the medical marijuana pharmaceutical space and capitalize on the industry’s evolution,” says Alex Somjen, President & CEO of Resinco.

“I am pleased to chair Resinco’s Advisory Board and work with the team to advance the Second Generation of the Medical cannabis industry,” said Sir Marc Feldmann, Chairman and Founder of ReFormation Pharmaceuticals. “Through rigorous clinical trials using FDA approved practices, we intend to accelerate ReFormation’s development of cannabis treatments triggering stem cell repair, where the medical benefits are based on hard science and government regulation.”

About Resinco Capital Partners

Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.

Website www.resincocp.com

About ReFormation Pharmaceuticals Corp

ReFormation Pharmaceuticals Corp is a medical cannabis pharmaceutical Company headquartered in Toronto, ON, with its Research and Development team at the University of Oxford. The Company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in-class therapeutic. The Company has identified a molecule that primes the body’s own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company’s research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford.

Website: <https://www.reformationpharma.com/>

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.



Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

RESINCO CAPITAL PARTNERS INC.:

Company Contact

Mr. Alexander Somjen, CEO
647-362-8998

Media Contact

Tim Gray, Account Director
KCSA Strategic Communications
Phone: 212.682.6300
Email: Resinco@KCSA.com